linjc16/ctgov huggingface dataset:
Milk as Treatment for Hypoglycemia

Study Overview
=================
Brief Summary
-----------------
Test hypothesis that milk can raise blood sugars as well as orange juice or glucose tablets without raising blood sugars too much the way that orange juice or glucose tablets sometimes do.

Detailed Description
-----------------
Subjects will wear a continuous glucose monitor prior to test to determine normal glucose levels. The morning of the test an IV will be inserted into the subject and insulin and saline drips will be started. Blood glucose levels will be checked every 10 minutes until the subject becomes hypoglycemic. IVs will be stopped at that time and subject will be given skim milk, orange juice or glucose tablets at that time. Blood will be drawn every 15 minutes until blood sugars stabilize. Blood draws will be analyzed to determine glucose, insulin, epinephrine, norepinephrine, glucagon, cortisol, growth hormone and GLP-1 levels. Procedure will be repeated two more times using other glucose methods (skim milk, orange juice or glucose tablets).

Official Title
-----------------
Milk as Treatment for Hypoglycemia

Conditions
-----------------
Type 1 Diabetes

Intervention / Treatment
-----------------
* Drug: D50 glucose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 1 Diabetes Able to be consented Able to wear continuous glucose monitor

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: D50 glucose|D50 glucose would be administered, if necessary.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Completion of 6 subjects. |  | One year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypoglycemia
The Status of Autonomic Tone Before Tourniquet Deflation During Total Knee Replacement

Study Overview
=================
Brief Summary
-----------------
This study evaluates the influences of the status of sympathovagal balance before tourniquet deflation on a decrease in arterial blood pressure following the deflation during total knee replacement arthroplasty

Detailed Description
-----------------
Patients present with different hemodynamic profiles after intraoperative tourniquet deflation during total knee replacement arthroplasty. Sympathovagal balance can be measured before tourniquet deflation and might determine the hemodynamic response to tourniquet deflation.

Official Title
-----------------
The Effects of Sympathovagal Balance Before Tourniquet Deflation on a Decrease in Arterial Blood Pressure Following the Deflation During Total Knee Replacement Arthroplasty

Conditions
-----------------
Hypotension, Blood Pressure, Low

Intervention / Treatment
-----------------
* Procedure: Tourniquet deflation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Society of Anesthesiologists physical status I - II Body mass index < 35 kg/m2 Exclusion Criteria: Coagulation deficiencies Known allergies to local anesthetics Neurologic deficit on the side being operated on Inflammation at the lumbar puncture site Cardiac conduction disorders or arrhythmias Congestive heart failure Serum electrolyte abnormalities Psychiatric disorders Patient's refusal Difficulty communicating with medical personnel Severe hypovolemia Increased intracranial pressure Severe aortic stenosis Severe mitral stenosis

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Tourniquet deflation<br>Tourniquet deflation after insertion of the prosthetic components during total knee replacement arthroplasty under spinal anesthesia | Procedure: Tourniquet deflation<br>* Tourniquet deflation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sympathovagal balance | The ratio of low-to-high frequency power of heart rate variability calculated from the 5-minute long electrocardiogram waveform | During 5 minutes before tourniquet deflation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Noninvasive hemodynamic parameters | Average cardiac index | During 5 minutes before tourniquet deflation | 
| Maximum percent change in mean arterial blood pressure | The discrepancy between minimum mean arterial blood pressure after tourniquet deflation and mean arterial blood pressure immediately before tourniquet deflation, which is divided by mean arterial pressure immediately before tourniquet deflation | During 10 minutes after tourniquet deflation |
Analysis of the Impact of the Undernutrition on the Cerebral Infarct in Thrombolized Patients

Study Overview
=================
Brief Summary
-----------------
Many clinical trials show that 30 to 50 % of the hospitalized patients are undernourished in various degrees. This prevalence didn't change since 15-20 years The fact is that the present undernutrition in the admission deteriorates during the hospitalization. Besides, the cerebral vascular accident (AVC) complicates the first days, in at least 50 % of the cases, the disorders of the gulp, which are a risk factor of acquired undernutrition. The nutrition holds an important place in the therapeutic coverage of the AVC. Nevertheless, the link between the undernutrition the entrance and the evolution of the AVC is at the moment only little known. The purpose is to study the impact of the undernutrition in the entrance to the hospital (undernutrition previous to the AVC), on the gravity and the evolution

Official Title
-----------------
Analysis of the Impact of the Undernutrition on the Cerebral Infarct in Thrombolized Patients

Conditions
-----------------
Thrombosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient admitted in hospital for vascular cerebral accident in 2015 thrombolytic treatment Exclusion Criteria: no thrombolytic treatment transcient ischaemic attack

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rankin score | measurement of Rankin score at the entrance and at the end of hospitalisation | Day 1; last day of hospitalisation |
GRK4 Polymorphisms Blood Pressure Response to Candesartan

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the association between GRK4 polymorphisms and essential hypertension in southwestern Han Chinese and test whether these polymorphisms were associated with the changes in blood pressure in patients with essential hypertension treated with angiotensin II Type antagonist candesartan.

Detailed Description
-----------------
All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥ 90 mmHg.

Conditions
-----------------
Essential Hypertension

Intervention / Treatment
-----------------
* Drug: Candesartan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: men and women with mild to moderate essential hypertension in southwestern Han Chinese Exclusion Criteria: subjects unwilling to participate or subjects did not have all measurement required, subjects who were on medications, which affect blood pressure or whose DNA failed to amplify and 8 with errors in Mendelian segregation

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: candesartan<br>All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20 mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥90 mmHg. | Drug: Candesartan<br>* To investigate the response to candesartan among southwestern Han Chinese with essential hypertrension<br>* Other names: GRK4 polymorphisms and essential hypertrension;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The subjects with GRK4 varirants may exert different response during 4 weeks of treatment with candesartan in patients with essential hypertension |  | two years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
men and women, in southwestern Han Chinese
Comprehensive Genomic Profiling Combined With Real Life Data of The German-Registry of Incidental Gallbladder Carcinoma

Study Overview
=================
Brief Summary
-----------------
Multicenter German- Registry of Incidental Gallbladder Carcinoma combining clinical real-world data and comprehensive genomic profiling. The registry collects medical data from clinical observation and molecular data derived from archival tumor tissue samples but does not define any medical intervention nor does it evaluate the efficacy or safety of the treatment decision made by the investigator.

Detailed Description
-----------------
In the largest cohort of IGBC patients ever analysed in such a comprehensive approach determine the course of patients in this rare kind of cancer combine cGP analysis of histological tumor samples with clinical real-life data to get a comprehensive overview on IGBC patients analysed and evaluate data to identify possible further (targeted) treatment possibilities analyze potential risk factors associated with gallbladder carcinoma assess the frequency of targetable mutations in IGBC

Official Title
-----------------
Comprehensive Genomic Profiling Combined With Real Life Data of The German-Registry of Incidental Gallbladder Carcinoma the CONGENIAL Analysis Sub-study of the GR

Conditions
-----------------
Gallbladder Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically confirmed diagnosis of incidental gallbladder carcinoma Patient ≥ 18 years old Patient already deceased Available tumor tissue (FFPE block) Exclusion Criteria: Patient under 18 years of age

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overall survival | Overall Survival is defined as the time from date of first surgery, to the date of death (due to any cause). | Through study completion, an average of 2 years | 
| proportion of patients with genomic alterations | The primary outcome variable of the molecular sub-project is the proportion of patients with actionable genomic alterations, defined as number of patients with actionable mutations divided by the number of patients with completed F1 CDx testing. Additionally, the two-sided 95% exact confidence interval (Clopper-Pearson) will be given. | Through study completion, an average of 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The proportion of patients with actionable genomic alterations in all patients | The proportion of patients with actionable genomic alterations in all patients, including those where no FoundationOne CDx test result may be obtained ± 95% confidence interval | Through study completion, an average of 2 years |
The ELUTES Clinical Trial

Study Overview
=================
Brief Summary
-----------------
ELUTES is a European multicenter, randomized, controlled, triple-blinded study designed to evaluate the ability of the Paclitaxel Eluting V-Flex Plus coronary stent to reduce restenosis in the coronary artery.

Official Title
-----------------
The ELUTES Clinical Trial (European Evaluation of Paclitaxel Eluting Stent)

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Device: coronary stent


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient must be eligible to undergo planned treatment of a single de novo lesion in a native coronary artery. Patient must be an acceptable candidate for coronary artery bypass surgery. Patient or legal guardian must have signed informed consent. Patient agrees to return at one month for an office visit to assess cardiovascular status and at 6 months for an office visit to assess cardiovascular status and for a diagnostic angiogram. Exclusion Criteria: Patient must be less than 18 years old. Patient has history of bleeding diathesis or coagulopathy or will refuse blood transfusions. Patient is simultaneously participating in another investigative interventional cardiovascular device or drug study. Patient has known hypersensitivity or contraindication to aspirin, clopidogrel, or stainless steel, or a sensitivity to contrast dye. Women of child bearing potential. Patient has other medical condition that may cause non-compliance with the protocol, confound the results, or is associated with limited life expectancy. Patient has been diagnosed with a myocardial infarction within 72 hours prior to procedure.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: coronary stent|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Angiographic in-stent % diameter stenosis and late loss at follow up. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major adverse events |  |  | 
| Total lesion revascularization |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
coronary artery, stent, drug eluting, patency, restenosis
Comparison of the Effects of Open and Endovascular Aortic Aneurysm Repair on Long-term Renal Function

Study Overview
=================
Brief Summary
-----------------
Compare the renal complication of endovascular and open repair of acute aortic dissection by including patient treated at NTUH in 2010 2013.

Official Title
-----------------
Comparison of the Effects of Open and Endovascular Aortic Aneurysm Repair on Long-term Renal Function

Conditions
-----------------
Long-term Renal Dysfunction

Participation Criteria
=================
Eligibility Criteria
-----------------
Patient underwent endovascular and open repair of aortic aneurysm at NTUH in 2010 2013 Age > 20 years old

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Long-term change of renal function (eGFR) after operation of aortic aneurysm |  | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival after operation of aortic aneurysm |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute kidney injury,aortic dissection
Salivary Flow Rate and Oral Function

Study Overview
=================
Brief Summary
-----------------
The purpose of this study was to investigate if salivary flow rate is important to maintain adequate oral functions.

Detailed Description
-----------------
Hyposalivation may damage oral functions. Therefore, the aim of this study was to evaluate whether patients under hyposalivation present damaged mastication and speech. Forty subjects composed 2 groups: Control (C) and hyposalivation (H). Masticatory performance (MP) was carried out using artificial material and a 10-sieve method. Mandibular movements during speech were obtained using a 3D jaw-tracking device. Neither mastication nor speech have been impaired by low salivary flow rate.

Official Title
-----------------
Effect of Hyposalivation on Mastication and Speech

Conditions
-----------------
Food Comminution, Jaw Movements

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Fully dentate Good general and oral health Exclusion Criteria: Signs or symptoms of temporomandibular disorders Parafunctions Malocclusion History of communication deficits or prior speech-language treatment

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 27 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control<br>Subjects with normal salivary flow rate | |
| Hyposalivation<br>Subjects presenting low salivary flow rate as a side effect of systemic isotretinoin therapy. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Saliva, Mastication, Communication
Point-Of-Care Chemistry Test (POCT) Effect on the Emergency Department (ED)

Study Overview
=================
Brief Summary
-----------------
The hypothesis of this study is that POCT will shorten ED turn-around-time (TAT) such as blood drawing TAT, lab TAT, and decision TAT.

Official Title
-----------------
A Randomized Controlled Multi-center Trial of a Point-Of-Care Chemistry Test for Reduction of Turnaround and Clinical Decision Time in the Emergency Department

Conditions
-----------------
Emergency Department, Length of Stay, Turnaround-time

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients older than 15 years clinically required to have chemistry lab tests agreement Exclusion Criteria: no agreement ESI level 1

Ages Eligible for Study
-----------------
Minimum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CLT<br>The patients whose blood are analyzed by conventional central laboratory. | |
| POCT<br>the patients group whose lab analyze by POCT device. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
A Prospective, Randomized, Single-blinded (Evaluator), Parallel, Multi-center, Phase 3 Trial in Bowel Preparation for Colonoscopy

Study Overview
=================
Brief Summary
-----------------
This is a prospective randomized study compared with active control arm. The investigators compare the colon cleansing in patients undergoing colonoscopy.

Official Title
-----------------
A Prospective, Randomized, Single-blinded (Evaluator), Parallel, Multi-center, Phase 3 Trial in Bowel Preparation for Colonoscopy

Conditions
-----------------
Bowel Preparation

Intervention / Treatment
-----------------
* Drug: TJP-008-1
* Drug: TJP-008-2
* Drug: Coolprep powder


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must provide written informed consent. Male and female outpatients and inpatients aged: ≥19 Patients BMI shoule be ≤ 30 Exclusion Criteria: Patients with past history within last 12 months or current episode of severe constipation Known glucose-6-phosphate dehydrogenase (G6PD) deficiency. Known phenylketonuria. Clinically relevant findings on physical examination based on the Investigator's judgment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: TJP-008-1<br> | Drug: TJP-008-1<br>* Subjects who are randomized into group TJP-008-1 will receive bowel preparation on the same-day.<br>|
| Experimental: TJP-008-2<br> | Drug: TJP-008-2<br>* Subjects who are randomized into group TJP-008-2 will receive bowel preparation from evening to next morning.<br>|
| Active Comparator: Coolprep powder<br> | Drug: Coolprep powder<br>* Subjects who are randomized into group Coolprep will receive bowel preparation from evening to next morning.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ratio of subjects With successful Bowel Cleansing |  | 1 day of scheduled colonoscopy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Easch segments ratio of subject with successful Bowel Cleansing |  | 1 day of scheduled colonoscopy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
bowel preparation